ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ZINECARD
Cytoprotective and supportive care agents
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

REMOVE SELECTED | COMPARE SELECTED

Drug Name:

ZINECARD Rx

Generic Name and Formulations:
Dexrazoxane 250mg, 500mg; per vial; pwd for IV infusion after reconstitution and dilution.

Company:
Pfizer Inc.

e-Prescribe this drug via Surescripts


Therapeutic Use:

Product Resources »
  • Product Information
  • Coupons, Samples & Vouchers
  • Patient Education and Assistance

Indications for ZINECARD:

To reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300mg/m2 and will continue to receive doxorubicin therapy to maintain tumor control.

Adult Dose for ZINECARD:

Give by slow IV push or rapid drip IV infusion. Doxorubicin should be administered within 30 minutes after starting Zinecard infusion. Administer in 10:1 ratio (eg, 500mg/m2 Zinecard: 50mg/m2 doxorubicin). Renal impairment (CrCl <40mL/min): reduce ratio to 5:1 (eg, 250mg/m2 Zinecard: 50mg/m2 doxorubicin). Hepatic impairment: may need to reduce doxorubicin dose, therefore Zinecard dose must be reduced (maintaining 10:1 ratio).

Children's Dose for ZINECARD:

Not recommended.

Pharmacological Class:

Chelating agent.

Contraindications:

Chemotherapy regimens that do not contain an anthracycline.

Warnings/Precautions:

Not recommended for use with initiation of doxorubicin. Renal or hepatic impairment. Monitor cardiac function and for myelosuppression; obtain CBCs frequently. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

Adverse Reactions:

Inj site pain, myelosuppression, possible secondary malignancies (see literature).

Elimination:

Renal.

Generic Availability:

YES

How Supplied:

Single-use vial—1 (w. diluent)